Trump said he will raise tariffs on $250 billion in Chinese goods to 30% and hike duties on another $300 billion in products to 15%.Politicsread more
Stocks dropped after Donald Trump ordered that U.S. manufacturers find alternatives to their operations in China.US Marketsread more
The final week of August could be highly volatile as markets fret over the economy and the latest developments in trade wars.Market Insiderread more
Federal Reserve Vice Chair Richard Clarida said Friday that the global economy has deteriorated in the past month.Marketsread more
The latest escalation in the trade war ups the odds the economy will fall into recession and that the Fed will aggressively cut rates.Market Insiderread more
Here are the products that stand to be the most affected by China's new tariffs on $75 billion worth of U.S. goods.Marketsread more
"We don't need China and, frankly, would be far better off without them," Trump tweeted.Politicsread more
Recent trade friction between the two Asian powerhouses has morphed into a dispute with political implications that go far beyond the region.Asia Politicsread more
"My only question is, who is our bigger enemy, Jay Powell or Chairman Xi?" Trump wrote amid a series of tweets that rattled markets Friday.Politicsread more
"I would love this to be clarified. We come to a deal on trade, boy, this market is up 10 to 15%, but without it's going to be worrisome," Jeremy Siegel says.Marketsread more
Tesla solar energy systems reportedly ignited at an Amazon warehouse in Redlands, California last June, and the Seattle e-commerce titan confirmed that it has no further plans...Technologyread more
Genetics testing company 23andMe wants users to rate their treatments for some conditions such as depression and asthma in a new feature it unveiled Thursday.
The company is starting with 18 common health conditions, including allergies, Type 2 diabetes, migraines and more. Only three of them are associated with a genetic report, said Jessie Inchauspe, the product manager who led the treatment page work.
Users can see what others have reported about the effectiveness of various treatments. The page also lists how many users experience the condition. About 4,500 users have shared 30,000 reviews since the company started testing the treatment pages over the past few weeks.
People can also access 23andMe's research.
The company doesn't have any immediate plans for how it will use the data it gathers from people's responses, but it could eventually use it to conduct more research, Inchauspe said.
23andMe has already collected data from the initial rollout. It found 36 percent of users experience seasonal allergies and top treatments include Flonase, Zyrtec, Claritin and Allegra.
"I would say in general as a company, we're really interested in helping customers with all aspects of their health," she said. "We don't have any immediate plans with the data, but you could imagine it leading to more detailed research in the future. Our mission as a company is all about giving people access to data and allowing them to use it."
Some experts have warned of the risks in giving consumers more control in their genetic health. 23andMe faced some backlash last month when the Food and Drug Administration approved an at-home test that screens for three mutations in a common type of breast cancer gene.
Insights into a patient's genetics can help in understanding one's risk and can be important for prevention, diagnosis and management for many medical conditions, said Dr. Peter Hulick, medical director of the center for personalized medicine at NorthShore University HealthSystem. But without proper understanding, results can create undue stress, he said.
"That is why it's extremely important for patients and physicians to work together to determine the right genetic tests at the right time and include other factors important in one's health history," he said in an email. "Efforts to increase availability of educational resources will help patients have important, and more meaningful conversations with their physicians/health care team."
With the new condition pages, 23andMe is not itself recommending any treatments. Instead, the company says it's giving people different information than they would find from a simple internet search.
A disclaimer at the bottom of the screen suggests users consider consulting a health-care professional if they're in need of treatments.